ONCO Stock Overview
A biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Onconetix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$21.40 |
| 52 Week Low | US$0.79 |
| Beta | 3.73 |
| 11 Month Change | -79.11% |
| 3 Month Change | -86.58% |
| 1 Year Change | -92.06% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation
Jan 24
Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia
Oct 11Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot
Aug 17Blue Water Vaccines in pact to study Alzheimer’s vaccine
Jul 20Blue Water Vaccines: Estimates And Expectations
May 17Shareholder Returns
| ONCO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -32.8% | 4.0% | 2.2% |
| 1Y | -92.1% | 18.3% | 32.6% |
Return vs Industry: ONCO underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: ONCO underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| ONCO volatility | |
|---|---|
| ONCO Average Weekly Movement | 30.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ONCO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ONCO's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Ralph Schiess | onconetix.gcs-web.com |
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. Fundamentals Summary
| ONCO fundamental statistics | |
|---|---|
| Market cap | US$9.04m |
| Earnings (TTM) | -US$53.12m |
| Revenue (TTM) | US$1.46m |
4.5x
P/S Ratio-0.1x
P/E RatioIs ONCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCO income statement (TTM) | |
|---|---|
| Revenue | US$1.46m |
| Cost of Revenue | US$2.30m |
| Gross Profit | -US$837.45k |
| Other Expenses | US$52.29m |
| Earnings | -US$53.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.40 |
| Gross Margin | -57.21% |
| Net Profit Margin | -3,629.25% |
| Debt/Equity Ratio | -52.6% |
How did ONCO perform over the long term?
See historical performance and comparison